Tarsus Pharmaceuticals, Inc. (TARS)Healthcare | Biotechnology | Irvine, United States | NasdaqGS
68.07 USD
-2.92
(-4.113%) ⇩
(Oct. 16, 2026, 4 p.m.
EDT)
After hours: 67.10 -0.97 (-0.970%) ⇩ (Oct. 16, 2026, 7:21 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 5:10 a.m. EDT
The investment case here is driven by a powerful divergence between deteriorating short-term momentum and exceptional long-term business execution. Fundamentally, the company has delivered a spectacular multi-year trajectory, surging nearly 241% over the last five years with three consecutive years of double-digit growth and a massive 69% revenue expansion recently. The balance sheet remains fortress-like with minimal debt and strong cash generation, validating the high valuation despite negative earnings typical of the biotech sector. However, the short-term chart tells a different story; the stock has stalled near its highs, trading below its 50-day moving average after a sharp pullback, and the statistical forecast offers almost no directional bias. This creates a tense setup where the long-term thesis is unassailable, but the immediate entry point feels precarious due to the lack of recent price confirmation and weak short-term statistical signals. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.179717 |
| MSTL | 0.207762 |
| AutoETS | 0.211366 |
| AutoTheta | 0.217191 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 35% |
| H-stat | 6.85 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.637 |
| Excess Kurtosis | -0.26 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 25.614 |
| Revenue per Share | 14.121 |
| Market Cap | 3,185,110,272 |
| Forward P/E | -136.14 |
| Beta | 0.45 |
| Profit Margins | -7.66% |
| Website | https://tarsusrx.com |
As of Oct. 10, 2026, 5:10 a.m. EDT: Speculators are positioning for significant upside volatility with heavy open interest in out-of-the-money calls (90, 95, 100 strikes) expiring late in 2026 and early 2027. Call volume is concentrated at strikes well above the current price, suggesting a bullish thesis on catalyst-driven price appreciation. Conversely, put activity is skewed toward deep out-of-the-money strikes (below 60) with relatively low volume compared to calls, indicating limited hedging demand for a crash and a lack of fear regarding downside protection.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.026600838 |
| Address1 | 17,700 Laguna Canyon Road |
| Address2 | Floor 4 |
| All Time High | 91.53 |
| All Time Low | 10.8 |
| Ask | 87.56 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 990,450 |
| Average Daily Volume3 Month | 832,918 |
| Average Volume | 832,918 |
| Average Volume10Days | 990,450 |
| Beta | 0.446 |
| Bid | 50.76 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 8.013 |
| City | Irvine |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 68.07 |
| Current Ratio | 3.198 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 70.87 |
| Day Low | 68.0 |
| Debt To Equity | 25.614 |
| Display Name | Tarsus Pharmaceuticals |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,786,017,600 |
| Earnings Call Timestamp Start | 1,786,017,600 |
| Earnings Timestamp | 1,786,019,400 |
| Earnings Timestamp End | 1,793,795,400 |
| Earnings Timestamp Start | 1,793,795,400 |
| Ebitda | -46,195,000 |
| Ebitda Margins | -0.07619 |
| Enterprise To Ebitda | -56.851 |
| Enterprise To Revenue | 4.331 |
| Enterprise Value | 2,626,236,416 |
| Eps Current Year | -4.8825 |
| Eps Forward | -0.5 |
| Eps Trailing Twelve Months | -1.08 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 74.776 |
| Fifty Day Average Change | -6.7060013 |
| Fifty Day Average Change Percent | -0.0896812 |
| Fifty Two Week Change Percent | -2.6600838 |
| Fifty Two Week High | 91.53 |
| Fifty Two Week High Change | -23.46 |
| Fifty Two Week High Change Percent | -0.2563094 |
| Fifty Two Week Low | 53.89 |
| Fifty Two Week Low Change | 14.18 |
| Fifty Two Week Low Change Percent | 0.2631286 |
| Fifty Two Week Range | 53.89 - 91.53 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,602,855,000,000 |
| Float Shares | 32,741,542 |
| Forward Eps | -0.5 |
| Forward P E | -136.14 |
| Free Cashflow | 67,467,872 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 370 |
| Fullday Change | -3.8899994 |
| Fullday Change Percent | -5.4796443 |
| Fullday Price | 67.1 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.82672 |
| Gross Profits | 501,264,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02686 |
| Held Percent Institutions | 0.99273 |
| Implied Shares Outstanding | 46,791,688 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-10-16 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction. In addition, it is developing the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. The company has a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for the development and commercialization of TP-03 in China for the treatment of Demodex blepharitis and meibomian gland disease. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. |
| Long Name | Tarsus Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 3,185,110,272 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_650383665 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -46,476,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 3,474,282,834 |
| Number Of Analyst Opinions | 10 |
| Open | 70.87 |
| Operating Cashflow | 74,158,000 |
| Operating Margins | -0.11447 |
| Overall Risk | 8 |
| Phone | 949 418 1801 |
| Post Market Change | -0.9700012 |
| Post Market Change Percent | -1.4250054 |
| Post Market Price | 67.1 |
| Post Market Time | 1,792,192,901 |
| Previous Close | 70.99 |
| Price Eps Current Year | -13.9416275 |
| Price Hint | 2 |
| Price To Book | 8.4949465 |
| Price To Sales Trailing12 Months | 5.253088 |
| Profit Margins | -0.07665 |
| Quick Ratio | 3.118 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.1 |
| Region | US |
| Regular Market Change | -2.9199982 |
| Regular Market Change Percent | -4.1132526 |
| Regular Market Day High | 70.87 |
| Regular Market Day Low | 68.07 |
| Regular Market Day Range | 68.07 - 70.87 |
| Regular Market Open | 70.87 |
| Regular Market Previous Close | 70.99 |
| Regular Market Price | 68.07 |
| Regular Market Time | 1,792,180,800 |
| Regular Market Volume | 2,432,250 |
| Return On Assets | -0.05485 |
| Return On Equity | -0.13683 |
| Revenue Growth | 0.694 |
| Revenue Per Share | 14.121 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 46,791,688 |
| Shares Percent Shares Out | 0.1297 |
| Shares Short | 6,070,928 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 6,011,550 |
| Short Name | Tarsus Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.1337 |
| Short Ratio | 7.31 |
| Source Interval | 15 |
| State | CA |
| Symbol | TARS |
| Target High Price | 116.0 |
| Target Low Price | 84.0 |
| Target Mean Price | 99.8 |
| Target Median Price | 101.0 |
| Total Cash | 449,689,984 |
| Total Cash Per Share | 10.247 |
| Total Debt | 88,811,000 |
| Total Revenue | 606,331,008 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.08 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 68.19547 |
| Two Hundred Day Average Change | -0.12547302 |
| Two Hundred Day Average Change Percent | -0.0018399025 |
| Type Disp | Equity |
| Volume | 2,432,250 |
| Website | https://tarsusrx.com |
| Zip | 92,618 |